Range of peak EBV reactivation in EBV seropositive patients
| EBV copies per 106 MNCs/treatment . | HC, no. (%) . | HCS, no. (%) . | RC, no. (%) . | CP, no. (%) . | All groups, no. (%) . |
|---|---|---|---|---|---|
| Negative | 4 (12) | 2 (8) | 0 (0) | 6 (21) | 12 (12) |
| Greater than 250-103 | 3 (9) | 7 (29) | 0 (0) | 1 (4) | 12 (12) |
| Greater than 103-104 | 18 (55) | 7 (29) | 1 (8) | 9 (36) | 36 (37) |
| Greater than 104-105 | 7 (21) | 6 (18) | 4 (31) | 6 (21) | 23 (23) |
| Greater than 105 | 1 (3) | 2 (8) | 8 (62) | 3 (12) | 15 (15) |
| EBV copies per 106 MNCs/treatment . | HC, no. (%) . | HCS, no. (%) . | RC, no. (%) . | CP, no. (%) . | All groups, no. (%) . |
|---|---|---|---|---|---|
| Negative | 4 (12) | 2 (8) | 0 (0) | 6 (21) | 12 (12) |
| Greater than 250-103 | 3 (9) | 7 (29) | 0 (0) | 1 (4) | 12 (12) |
| Greater than 103-104 | 18 (55) | 7 (29) | 1 (8) | 9 (36) | 36 (37) |
| Greater than 104-105 | 7 (21) | 6 (18) | 4 (31) | 6 (21) | 23 (23) |
| Greater than 105 | 1 (3) | 2 (8) | 8 (62) | 3 (12) | 15 (15) |
HC indicates horse ATG/CsA; HCS, horse ATG/CsA/sirolimus; RC, rabbit ATG/CsA; CP, alemtuzumab; MNCs, mononuclear cells genome equivalents.